Labcorp Holdings Inc. · NYSE (us_market)
Healthcare · Diagnostics & Research · United States
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, the company offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI-enabled Test Selection, a generative AI-enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. The company has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-03-04$256.81 RISE2025-04-21$212.22 PEAK2025-07-01$264.26 119d | -17.4% 48d | Missed | Missed | — | — | +24.5% 71d | Missed |
DROP2024-02-14$228.11 RISE2024-05-29$192.50 PEAK2024-08-02$236.00 170d | -15.6% 105d | Missed | Missed | — | — | +22.6% 65d | Missed |
DROP2023-01-23$221.50 RISE2023-05-30$182.07 PEAK2023-07-25$221.70 183d | -17.8% 127d | Missed | Missed | — | — | +21.8% 56d | Missed |
DROP2022-07-29$225.25 RISE2022-10-11$175.52 PEAK2022-11-11$213.89 105d | -22.1% 74d | Missed | Missed | — | — | +21.9% 31d | Missed |
DROP2022-02-10$242.43 RISE2022-06-14$183.73 PEAK2022-07-29$225.25 169d | -24.2% 124d | Missed | Missed | — | — | +22.6% 45d | Missed |
DROP2020-02-14$167.77 RISE2020-06-24$134.96 PEAK2020-07-27$172.94 164d | -19.6% 131d | Missed | Missed | — | — | +28.1% 33d | Missed |
DROP2020-02-14$167.77 RISE2020-03-23$89.62 PEAK2020-06-08$156.74 115d | -46.6% 38d | Missed | Missed | — | — | +74.9% 77d | Missed |
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
LH vs. MEDP: Which Stock Is the Better Value Option?
Medtronic's Q4 results may get a lift from broad MedSurg growth, strong Cardiovascular demand and continued momentum in Diabetes.
Medtronic's Q4 results may get a lift from broad MedSurg growth, strong Cardiovascular demand and continued momentum in Diabetes.
Labcorp Holdings has lagged behind the broader market over the past year, yet analysts remain highly optimistic about the stock’s prospects.
Labcorp Holdings has lagged behind the broader market over the past year, yet analysts remain highly optimistic about the stock’s prospects.
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...
Labcorp (LH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Labcorp (LH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
LH gains from specialty testing growth, acquisitions and AI initiatives, but currency swings and macro pressures remain risks.
LH gains from specialty testing growth, acquisitions and AI initiatives, but currency swings and macro pressures remain risks.
Earlier in May 2026, Labcorp announced an expanded collaboration with Epic, making its full test menu available through Aura, Epic's unified platform that simplifies lab ordering, interfaces and test access for hospitals and health systems using Epic nationwide. A few days later, Labcorp launched MyLabcorp™, an AI-powered mobile app that uses OpenAI models to provide personalized lab result explanations and health education, highlighting the company's push to integrate advanced technology...
Earlier in May 2026, Labcorp announced an expanded collaboration with Epic, making its full test menu available through Aura, Epic's unified platform that simplifies lab ordering, interfaces and test access for hospitals and health systems using Epic nationwide. A few days later, Labcorp launched MyLabcorp™, an AI-powered mobile app that uses OpenAI models to provide personalized lab result explanations and health education, highlighting the company's push to integrate advanced technology...
Illumina, Inc. (NASDAQ: ILMN) today confirmed the election of David P. King to its Board of Directors, effective immediately following the company's annual meeting of shareholders. Mr. King's election marks an important addition to Illumina's Board as the company accelerates its clinical strategy to integrate genomics more broadly into the standard of care.
DHR's Biotechnology segment posts 7% core revenue growth as bioprocessing demand stayed strong and equipment orders jumped despite headwinds.
DHR's Biotechnology segment posts 7% core revenue growth as bioprocessing demand stayed strong and equipment orders jumped despite headwinds.
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the launch of MyLabcorp™, an AI-powered mobile app that brings together lab results, AI-enabled features and clinical guideline-based content in a secure, personalized mobile experience. The app is designed to give users additional context about their health and support more informed conversations with healthcare providers.
MyLabcorp connects lab results, educational content and AI-enabled features in a secure, personalized mobile experienceLeverages OpenAI models designed to help users understand their results, ask questions and identify
Replit, one of the hottest names in vibe coding, ranks No. 42 on CNBC’s 2026 Disruptor 50 list.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| LH | +1.65% | -9.22% | +3.66% | +4.45% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -1.32% | -3.50% | +7.10% | -8.23% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 3.86M | $1.03B | 0.04% | Added+1.0% | 2026-03-31 |
| FidelityFMR | fundamental | 1.29M | $343.76M | 0.02% | Trimmed-3.8% | 2026-03-31 |
| Wellington | fundamental | 959.1K | $255.91M | 0.05% | Trimmed-51.1% | 2026-03-31 |
| Citadel | multi-strat | 259.6K | $69.25M | 0.09% | New | 2026-03-31 |
| Bridgewater | macro | 11.2K | $2.98M | 0.01% | Trimmed-35.6% | 2026-03-31 |
| TRowePrice | fundamental | 119.3K | $31.84K | 0.00% | Trimmed-0.7% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-13 | Schechter Adam H | President & CEO | S Open-market sale | 5,903 | $254.50 | −$1.50M |
| 2026-03-30 | Bailey Megan D. | EVP, Pres, Central Labs & Intl | F Tax withholding | 481 | $268.38 | −$129.1K |
| 2026-03-30 | Bailey Megan D. | EVP, Pres, Central Labs & Intl | A Grant / award | 1,184 | — | +$0 |
| 2026-03-30 | Kyle Kathryn W | EVP, Chief Legal Officer | F Tax withholding | 451 | $268.38 | −$121.0K |
| 2026-03-30 | Kyle Kathryn W | EVP, Chief Legal Officer | A Grant / award | 1,584 | — | +$0 |
| 2026-03-30 | Meltzer Jonathan C | EVP, Operations | S Open-market sale | 839 | $267.05 | −$224.1K |
| 2026-03-30 | Meltzer Jonathan C | EVP, Operations | F Tax withholding | 711 | $268.38 | −$190.8K |
| 2026-03-30 | Meltzer Jonathan C | EVP, Operations | A Grant / award | 2,388 | — | +$0 |
| 2026-03-30 | Oyegunwa Akinbolade | EVP, CIO & CTO | F Tax withholding | 382 | $268.38 | −$102.5K |
| 2026-03-30 | Oyegunwa Akinbolade | EVP, CIO & CTO | A Grant / award | 1,340 | — | +$0 |
| 2026-03-30 | Summy Amy B. | EVP, Chief Marketing Officer | F Tax withholding | 1,836 | $268.38 | −$492.7K |
| 2026-03-30 | Summy Amy B. | EVP, Chief Marketing Officer | A Grant / award | 3,994 | — | +$0 |
| 2026-03-30 | van der Vaart Sandra D | EVP, Corporate Affairs | F Tax withholding | 2,722 | $268.38 | −$730.5K |
| 2026-03-30 | van der Vaart Sandra D | EVP, Corporate Affairs | A Grant / award | 6,382 | — | +$0 |
| 2026-03-30 | Vaughn Bryan T | EVP, Diagnostics | F Tax withholding | 451 | $268.38 | −$121.0K |
| 2026-03-30 | Vaughn Bryan T | EVP, Diagnostics | A Grant / award | 1,584 | — | +$0 |
| 2026-03-30 | Wilkinson Peter J | SVP, Chief Accounting Officer | S Open-market sale | 1,633 | $267.05 | −$436.1K |
| 2026-03-30 | Wilkinson Peter J | SVP, Chief Accounting Officer | F Tax withholding | 755 | $268.38 | −$202.6K |
| 2026-03-30 | Wilkinson Peter J | SVP, Chief Accounting Officer | A Grant / award | 2,388 | — | +$0 |
| 2026-03-30 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | F Tax withholding | 863 | $268.38 | −$231.6K |
| 2026-03-30 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | A Grant / award | 1,986 | — | +$0 |
| 2026-03-30 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | F Tax withholding | 4,042 | $268.38 | −$1.08M |
| 2026-03-30 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | A Grant / award | 9,304 | — | +$0 |
| 2026-03-30 | Schroeder Mark S | EVP, Pres Diagnostics & COO | F Tax withholding | 1,468 | $268.38 | −$394.0K |
| 2026-03-30 | Schroeder Mark S | EVP, Pres Diagnostics & COO | A Grant / award | 2,968 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-23upcoming | 4.78 | — | — |
| 2026-04-30 | 4.12 | 4.25 | +3.26% |
| 2026-02-17 | 3.94 | 4.07 | +3.25% |
| 2025-10-28 | 4.14 | 4.18 | +1.01% |
| 2025-07-24 | 4.16 | 4.35 | +4.47% |
| 2025-04-29 | 3.73 | 3.84 | +2.82% |
| 2025-02-06 | 3.39 | 3.45 | +1.71% |
| 2024-10-24 | 3.49 | 3.50 | +0.23% |
| 2024-08-01 | 3.77 | 3.94 | +4.49% |
| 2024-04-25 | 3.48 | 3.68 | +5.65% |
| 2024-02-15 | 3.26 | 3.30 | +1.27% |
| 2023-10-26 | 3.33 | 3.38 | +1.54% |
| 2023-07-27 | 3.45 | 3.42 | -0.97% |
| 2023-04-25 | 3.96 | 3.82 | -3.56% |
| 2023-02-16 | 4.14 | 4.14 | +0.11% |
| 2022-10-27 | 4.68 | 4.68 | +0.04% |